跳至主要内容
临床试验/NCT04993625
NCT04993625进行中(未招募)不适用

Selective Avoidanve of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy In HER-2 Positive/Triple Negative Breast Cancer Patients With Excellent Radiologic Response to the Breast and Axilla, Prospective, Multi-center, Single-arm Study

Jeong Eon Lee1 个研究点 分布在 1 个国家目标入组 178 人开始时间: 2021年9月27日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
178
试验地点
1
主要终点
5-year recurrence free survival

研究概览

简要总结

The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when physical examination expected complete remission. And radiological expected Tumor size ≤ 2cm or non-mass enhancement ≤ 4cm.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 69 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

5-year recurrence free survival

时间窗: 5-year after last patient enrollment

The aims of this study is to evaluate 5 year recurrence free survival when omit sentinel lymph node biopsy after neoadjuvant chemotherapy in triple negative or HER-2 positive breast cancer patients when expected complete remission.

次要结局

  • IBTR(5-year after last patient enrollment)
  • LRFS(5-year after last patient enrollment)
  • OS(5-year after last patient enrollment)
  • toxicity rate(5-year after last patient enrollment)
  • Adverse Event(5-year after last patient enrollment)
  • CSS(5-year after last patient enrollment)
  • IARI(5-year after last patient enrollment)
  • EORTC QLQ(5-year after last patient enrollment)

研究者

发起方
Jeong Eon Lee
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Jeong Eon Lee

Samsung Medical Center

Samsung Medical Center

研究点 (1)

Loading locations...

相似试验